A comparative study on endovascular treatment of (sub)acute critical limb ischemia

• Verfasst von: Kronlage, Mariya [VerfasserIn]
• Verfasst von: Heilmeier, Britta [VerfasserIn]
• Verfasst von: Müller, Oliver J. [VerfasserIn]
• Verfasst von: Katus, Hugo [VerfasserIn]
• Verfasst von: Erbel, Christian [VerfasserIn]
• Titel: A comparative study on endovascular treatment of (sub)acute critical limb ischemia
• Titelzusatz: mechanical thrombectomy vs thrombolysis
• Verf.angabe: Mariya Kronlage, Ilka Printz, Britta Vogel, Erwin Blessing, Oliver J. Müller, Hugo A. Katus, Christian Erbel
• E-Jahr: 2017
• Jahr: 18 April 2017
• Umfang: 9 S.
• Fussnoten: Gesehen am 25.04.2018
• Titel Quelle: Enthalten in: Drug design, development and therapy
• Ort Quelle: Albany, Auckland : Dove Medical Press, 2007
• Jahr Quelle: 2017
• Band/Heft Quelle: 11(2017), Seite 1233-1241
• ISSN Quelle: 1177-8881
• DOI: doi:10.2147/DDDT.S131503
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 157235996X

Abstract

Objective: The aim of this study was to compare different interventional methods for treatment of (sub)acute limb ischemia upon thrombotic occlusions of the lower extremity in terms of their safety and efficacy in a tertiary hospital setting. Design: This is a retrospective, single-center study of non-randomized data. Methods: A total of 202 patients, including 26 critically ill patients, underwent rotational thrombectomy (Rotarex®), local thrombolysis (recombinant tissue plasminogen activator), or combination of both at the University Hospital Heidelberg (2006–2015). The different interventional procedures were compared in terms of overall and amputation-free survival, as well as patency in a 1-year follow-up (Kaplan–Meier analysis). Results: The study demonstrated a primary revascularization success of >98% in all groups. One year after revascularization, primary and secondary patency after mechanical thrombectomy alone were significantly better in comparison to local thrombolysis or a combination of Rotarex® and lysis (63% and 85%, P<0.05). Overall survival 12 months after intervention reached up to 96% in noncritically ill patients, and amputation-free survival was 94.3% in all three groups. Mean hospitalization duration and rate of major bleedings were significantly increased after thrombolysis compared to Rotarex® (P<0.05). Conclusion: In patients with (sub)acute limb ischemia, Rotarex® mechanical thrombectomy represents a safe and effective alternative to thrombolysis and is associated with a reduced rate of major bleedings, shorter hospitalization durations, and lower costs.